Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report.

Ibrutinib Paronychia Periungual granulation Side effect

Journal

Skin appendage disorders
ISSN: 2296-9195
Titre abrégé: Skin Appendage Disord
Pays: Switzerland
ID NLM: 101670617

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 19 07 2019
accepted: 28 08 2019
entrez: 6 2 2020
pubmed: 6 2 2020
medline: 6 2 2020
Statut: ppublish

Résumé

Ibrutinib is an oral covalent inhibitor of the Bruton's tyrosine kinase pathway and is approved for the treatment of B-cell malignancies including chronic lymphocytic leukaemia, mantle cell lymphoma, and Waldenström's macroglobulinaemia. It is generally a drug of choice for high-risk patients with indolent lymphomas. The safety profile of ibrutinib appears to be tolerable, with well-known side effects such as infections and haematologic complications. Additionally, dermatological adverse reactions with ibrutinib therapy have been reported to encompass maculopapular rash and hair/nail abnormalities. Here, we present a case of ibrutinib-induced paronychia and periungual granulation in a 40-year-old woman. To the best of our knowledge, this is the third description of ibrutinib-induced paronychia and periungual granulation.

Identifiants

pubmed: 32021859
doi: 10.1159/000502986
pii: sad-0006-0032
pmc: PMC6995981
doi:

Types de publication

Case Reports

Langues

eng

Pagination

32-36

Informations de copyright

Copyright © 2019 by S. Karger AG, Basel.

Déclaration de conflit d'intérêts

None of the authors declare any financial support or relationships that may pose a conflict of interest regarding this paper.

Références

Acta Haematol. 2019;141(4):254-255
pubmed: 30965323
Clin Exp Dermatol. 1986 Mar;11(2):148-52
pubmed: 3720014
J Immunol. 2007 Sep 15;179(6):3872-80
pubmed: 17785824
Drugs Context. 2018 Jul 17;7:212516
pubmed: 30038659
Drug Saf Case Rep. 2017 Nov 1;4(1):15
pubmed: 29094220
J Am Acad Dermatol. 2015 Feb;72(2):203-18; quiz 219-20
pubmed: 25592338
Eur J Dermatol. 2016 Jun 1;26(3):232-9
pubmed: 27019511
J Am Acad Dermatol. 2012 Sep;67(3):400-8
pubmed: 22088429
Am J Clin Dermatol. 2018 Nov;19(Suppl 1):31-39
pubmed: 30374901
Crit Rev Oncol Hematol. 2019 Apr;136:56-63
pubmed: 30878129
Dermatology. 2003;207(3):324-5
pubmed: 14571080
An Bras Dermatol. 2016 Apr;91(2):223-5
pubmed: 27192525
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
pubmed: 20457564
Haematologica. 2017 Oct;102(10):1629-1639
pubmed: 28775119
JAMA Dermatol. 2016 Jun 1;152(6):698-701
pubmed: 26982511
Recent Results Cancer Res. 2014;201:259-67
pubmed: 24756799
Indian Dermatol Online J. 2018 Sep-Oct;9(5):293-298
pubmed: 30258794
Biomedicine (Taipei). 2015 Nov;5(4):19
pubmed: 26613930

Auteurs

Ahu Yorulmaz (A)

Department of Dermatology, Ankara Bilkent City Hospital, Ankara, Turkey.

Basak Yalcin (B)

Department of Dermatology, Ankara Bilkent City Hospital, Ankara, Turkey.

Classifications MeSH